Brokers Offer Predictions for Johnson & Johnson’s FY2017 Earnings (JNJ)
Johnson & Johnson (NYSE:JNJ) – Research analysts at Jefferies Group boosted their FY2017 earnings per share estimates for Johnson & Johnson in a research note issued to investors on Wednesday. Jefferies Group analyst J. Holford now expects that the company will post earnings per share of $7.22 for the year, up from their previous estimate of $7.11. Jefferies Group has a “Buy” rating and a $157.00 price objective on the stock.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The firm had revenue of $18.84 billion for the quarter, compared to the consensus estimate of $18.94 billion. During the same quarter in the prior year, the company posted $1.74 earnings per share. The business’s revenue was up 1.9% on a year-over-year basis.
TRADEMARK VIOLATION WARNING: “Brokers Offer Predictions for Johnson & Johnson’s FY2017 Earnings (JNJ)” was reported by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/10/12/brokers-offer-predictions-for-johnson-johnsons-fy2017-earnings-jnj.html.
A number of other equities analysts have also recently issued reports on the stock. UBS AG reiterated a “buy” rating and issued a $148.00 price target (up previously from $136.00) on shares of Johnson & Johnson in a research note on Wednesday, July 19th. Goldman Sachs Group, Inc. (The) cut shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and upped their price target for the stock from $125.00 to $130.00 in a research note on Wednesday, September 20th. BMO Capital Markets reiterated a “buy” rating and issued a $145.00 price target on shares of Johnson & Johnson in a research note on Friday, September 1st. Alembic Global Advisors cut shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research note on Friday, July 21st. Finally, BidaskClub upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 17th. Five research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $136.02.
Johnson & Johnson (NYSE:JNJ) opened at 136.65 on Thursday. The firm has a market cap of $366.77 billion, a P/E ratio of 23.12 and a beta of 0.78. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08. The firm’s 50-day moving average is $132.32 and its 200 day moving average is $130.07.
A number of institutional investors have recently added to or reduced their stakes in the stock. Harding Loevner LP bought a new position in Johnson & Johnson in the 2nd quarter worth approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the period. Lenox Wealth Advisors Inc. boosted its stake in Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares during the period. IHT Wealth Management LLC boosted its stake in Johnson & Johnson by 46.4% in the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after purchasing an additional 3,467 shares during the period. Finally, Mountain Capital Investment Advisors Inc bought a new position in Johnson & Johnson in the 2nd quarter worth approximately $124,000. 65.90% of the stock is owned by institutional investors.
In related news, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.
The company also recently announced a quarterly dividend, which was paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th were issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.46%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s dividend payout ratio is 56.76%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.